GT-002 is under clinical development by Gabather and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect GT-002’s likelihood of approval (LoA) and phase transition for Schizophrenia took place on 12 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GT-002 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
GT-002 is under development for the treatment of psychosis, depression, schizophrenia and Alzheimer's disease. It is administered through oral route. It is a small molecule that acts by targeting gamma aminobutyric acid (GABA) A receptor (GABR).
Gabather develops drugs for the treatment of central nervous system disorders. The company spans its expertise in the development of anti-psychotics, anti-depressants and anxiolytics, analgesics and cognition-enhancing treatments. It offers drug candidates in form of small molecules that integrate with the GABAA (?-Aminobutyric acid type A) receptor complex in the brain. The company’s target diseases include Alzheimer’s, sleep disorder, pain, anxiety, epilepsy, muscle tension and addiction, among others. Gabather is headquartered in Sodertalje, Sodermanland, Sweden.
Quick View GT-002 LOA Data
|Highest Development Stage|